PT772451E - Tratamento da diabetes mellitus tipo ii com antagonistas de amilina - Google Patents

Tratamento da diabetes mellitus tipo ii com antagonistas de amilina

Info

Publication number
PT772451E
PT772451E PT96921467T PT96921467T PT772451E PT 772451 E PT772451 E PT 772451E PT 96921467 T PT96921467 T PT 96921467T PT 96921467 T PT96921467 T PT 96921467T PT 772451 E PT772451 E PT 772451E
Authority
PT
Portugal
Prior art keywords
diabetes mellitus
amiline
antagonists
treatment
mellitus type
Prior art date
Application number
PT96921467T
Other languages
English (en)
Portuguese (pt)
Inventor
Orville G Kolterman
Robert G Thompson
John F Mullane
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of PT772451E publication Critical patent/PT772451E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT96921467T 1995-06-07 1996-06-07 Tratamento da diabetes mellitus tipo ii com antagonistas de amilina PT772451E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/483,188 US6143718A (en) 1995-06-07 1995-06-07 Treatment of Type II diabetes mellutis with amylin agonists

Publications (1)

Publication Number Publication Date
PT772451E true PT772451E (pt) 2003-04-30

Family

ID=23919034

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96921467T PT772451E (pt) 1995-06-07 1996-06-07 Tratamento da diabetes mellitus tipo ii com antagonistas de amilina

Country Status (19)

Country Link
US (2) US6143718A (cg-RX-API-DMAC7.html)
EP (1) EP0772451B1 (cg-RX-API-DMAC7.html)
JP (1) JP4009319B2 (cg-RX-API-DMAC7.html)
AT (1) ATE228849T1 (cg-RX-API-DMAC7.html)
AU (1) AU721489B2 (cg-RX-API-DMAC7.html)
BG (1) BG101230A (cg-RX-API-DMAC7.html)
CA (1) CA2196999C (cg-RX-API-DMAC7.html)
CZ (1) CZ289043B6 (cg-RX-API-DMAC7.html)
DE (1) DE69625157T2 (cg-RX-API-DMAC7.html)
DK (1) DK0772451T3 (cg-RX-API-DMAC7.html)
ES (1) ES2187659T3 (cg-RX-API-DMAC7.html)
HU (1) HUP9700368A3 (cg-RX-API-DMAC7.html)
IN (1) IN181672B (cg-RX-API-DMAC7.html)
NO (1) NO970519L (cg-RX-API-DMAC7.html)
PT (1) PT772451E (cg-RX-API-DMAC7.html)
RU (1) RU2166958C2 (cg-RX-API-DMAC7.html)
SK (1) SK18697A3 (cg-RX-API-DMAC7.html)
WO (1) WO1996040220A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA964838B (cg-RX-API-DMAC7.html)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
DK0717635T3 (da) * 1993-09-07 2000-12-11 Amylin Pharmaceuticals Inc Fremgangsmåder til reduktion af gastrointestinal motilitet
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US7101853B2 (en) * 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
AU760609B2 (en) * 1998-01-09 2003-05-15 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6087334A (en) * 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides
ES2316757T3 (es) * 2002-01-08 2009-04-16 Amylin Pharmaceuticals, Inc. Uso de agonistas de amilina para modular trigliceridos.
AU2003259131A1 (en) * 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
CA2525168A1 (en) * 2003-05-14 2004-12-02 Emisphere Technologies, Inc. Compositions for delivering peptide yy and pyy agonists
WO2005014022A1 (en) * 2003-07-16 2005-02-17 Develogen Aktiengesellschaft Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
JP2008500281A (ja) * 2004-02-11 2008-01-10 アミリン・ファーマシューティカルズ，インコーポレイテッド アミリンファミリーペプチドおよびそれらを作成し使用するための方法
CA2556923A1 (en) * 2004-02-20 2005-09-09 Rinat Neuroscience Corp. Methods of treating obesity or diabetes using nt-4/5
US7399744B2 (en) * 2004-03-04 2008-07-15 Amylin Pharmaceuticals, Inc. Methods for affecting body composition
US7452868B2 (en) * 2005-03-11 2008-11-18 Indevus Pharmaceuticals, Inc. Controlled release formulations of octreotide
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
RU2008131939A (ru) * 2006-02-02 2010-02-10 Ринат Ньюросайенс Корп. (Us) Способы лечения нежелательной потери веса или нарушений приема пищи агонистами trkb
JP2009525319A (ja) * 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法
US20100086997A1 (en) * 2006-12-20 2010-04-08 Rinat Enuroscience Corp TrkB Agonists for Treating Autoimmune Disorders
WO2009064298A1 (en) * 2007-11-14 2009-05-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
JP5622725B2 (ja) * 2008-06-25 2014-11-12 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド．Ｅｎｄｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｓｏｌｕｔｉｏｎｓｉｎｃ． エキセナチド及び他のポリペプチド類の持続的送達
AU2009262263B2 (en) * 2008-06-25 2014-08-14 Endo Pharmaceuticals Solutions Inc. Octreotide implant having a release agent
RS59913B1 (sr) 2008-10-17 2020-03-31 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
JP2009149684A (ja) * 2009-03-11 2009-07-09 Amylin Pharmaceut Inc アミリン作動薬ペプチド用製剤
BRPI1009392A2 (pt) * 2009-03-12 2016-03-08 Nordic Bioscience As "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
US20110118178A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
CA2780043C (en) 2009-11-13 2019-01-29 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist and methionine
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
SG187904A1 (en) 2010-08-30 2013-04-30 Sanofi Aventis Deutschland Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
BR102013017626A2 (pt) * 2013-06-14 2015-02-10 Univ Rio De Janeiro Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças.
ES2887370T3 (es) * 2014-09-04 2021-12-22 Novo Nordisk As Nuevo agonista del receptor de amilina y calcitonina
SI3229828T1 (sl) 2014-12-12 2023-06-30 Sanofi-Aventis Deutschland Gmbh Formulacija s fiksnim razmerjem inzulin glargin/liksisenatid
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5367052A (en) * 1987-04-27 1994-11-22 Amylin Pharmaceuticals, Inc. Amylin peptides
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
US5266561A (en) * 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
US5321008A (en) * 1991-01-10 1994-06-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
MD960317A (ro) * 1991-11-19 1998-05-31 Anylin Pharmaceuticals, Inc. Noile peptide-agoniste ale amilinei şi utilizarea lor
US5376638A (en) * 1992-09-01 1994-12-27 Amylin Pharmaceuticals, Inc. Methods for treating renin-related disorders with amylin antagonists
DK0717635T3 (da) * 1993-09-07 2000-12-11 Amylin Pharmaceuticals Inc Fremgangsmåder til reduktion af gastrointestinal motilitet
US6143718A (en) * 1995-06-07 2000-11-07 Amylin Pharmaceuticals, Inc. Treatment of Type II diabetes mellutis with amylin agonists
US6087334A (en) 1998-08-21 2000-07-11 Amylin Pharmaceuticals, Inc. Anti-diabetic peptides

Also Published As

Publication number Publication date
AU721489B2 (en) 2000-07-06
BG101230A (en) 1997-10-31
DE69625157T2 (de) 2003-04-17
AU6268596A (en) 1996-12-30
US6417164B1 (en) 2002-07-09
EP0772451A4 (en) 1998-09-30
CA2196999A1 (en) 1996-12-19
HUP9700368A3 (en) 2001-03-28
DK0772451T3 (da) 2003-01-06
HU9700368D0 (en) 1997-04-28
CA2196999C (en) 2012-09-04
ES2187659T3 (es) 2003-06-16
CZ33797A3 (en) 1997-07-16
CZ289043B6 (cs) 2001-10-17
NO970519D0 (no) 1997-02-05
WO1996040220A1 (en) 1996-12-19
NO970519L (no) 1997-04-07
DE69625157D1 (de) 2003-01-16
ZA964838B (en) 1997-02-24
RU2166958C2 (ru) 2001-05-20
US6143718A (en) 2000-11-07
EP0772451A1 (en) 1997-05-14
HUP9700368A2 (hu) 1998-06-29
JPH10503785A (ja) 1998-04-07
ATE228849T1 (de) 2002-12-15
SK18697A3 (en) 1998-02-04
JP4009319B2 (ja) 2007-11-14
EP0772451B1 (en) 2002-12-04
IN181672B (cg-RX-API-DMAC7.html) 1998-08-29

Similar Documents

Publication Publication Date Title
PT772451E (pt) Tratamento da diabetes mellitus tipo ii com antagonistas de amilina
EA199700119A1 (ru) Соединения, оказывающие эффекты на системы, связанные с серотонином
MX9203755A (es) Dispositivo de suministro iontoforetico de drogas o agentes terapeuticos, dotado de un adhesivo de electrotransporte.
CA2146973A1 (en) Uses of tgf-.beta. receptor fragment as a therapeutic agent
EP0820769A3 (en) Use of benzothiophenes for the manufacture of a medicament for the treatment of diseases associated with an excess of tachykinis
DE69429603D1 (de) Iontophoresematrix
DK1063995T3 (da) Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator
DE68910799D1 (de) Faserbehandlungszusammensetzung.
DE69839423D1 (de) Verfahren zur prevention von gastritis unter verwendung von amylin oder amylin agonisten
BR9708027A (pt) Métodos de tratamento ou prevenção de cistite entersticial
DE68913088D1 (de) Faserbehandlungszusammensetzung.
EA199800535A1 (ru) Способ лечения боли
PT869785E (pt) 4-hidroxicumarina-3-carboxamidas para o tratamento de diabetes mellitus nao insulinodependente
SE8800461D0 (sv) Farmaceutisk komposition
FI973257A0 (fi) Menetelmä polttoaineen valmistamiseksi pehmeästä mäntysuovasta
ES2117008T3 (es) Metodo de tratamiento con amperozida de la esquizofrenia resistente a la terapia.
NO984198D0 (no) Fremgangsmåte for behandling av aggresjon
EA199800818A1 (ru) Способ лечения бессонницы
DE19680740T1 (de) Faserbehandlungszusammensetzung
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами
BR1100506A (pt) Composição para o tratamento de um ser humano sofrendo de um distúrbio intestinal.
KR950016724U (ko) 갯벌을 이용한 사우나탕
NO950114L (no) Amylin-antagonister og agonister
AU2067297A (en) Method for treating substance abuse
KR970020893U (ko) 주사용 바늘